(Q38151948)

29 August 2017

title

Will the next generation of basal insulins offer clinical advantages? (English)

1 reference

29 August 2017

A J Garber

1

1 reference

29 August 2017

publication date

31 October 2013

1 reference

Diabetes, Obesity and Metabolism

29 August 2017

published in

1 reference

29 August 2017

volume

16

1 reference

29 August 2017

issue

6

1 reference

29 August 2017

page(s)

483-491

1 reference

Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues

29 August 2017

cites work

1 reference

Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS)

21 January 2018

1 reference

Is glycemic control improving in U.S. adults?

21 January 2018

1 reference

Evaluation of risk factors for development of complications in Type II diabetes in Europe

21 January 2018

1 reference

Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America

21 January 2018

1 reference

How hypoglycaemia can affect the life of a person with diabetes

21 January 2018

1 reference

The impact of non-severe hypoglycemic events on work productivity and diabetes management

21 January 2018

1 reference

Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey

21 January 2018

1 reference

Decreased epinephrine responses to hypoglycemia during sleep.

21 January 2018

1 reference

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

21 January 2018

1 reference

Refining basal insulin therapy: what have we learned in the age of analogues?

21 January 2018

1 reference

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study

21 January 2018

1 reference

Insulin detemir: A historical perspective on a modern basal insulin analogue

21 January 2018

1 reference

The Treat-to-Target Trial and related studies

21 January 2018

1 reference

Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies

21 January 2018

1 reference

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

21 January 2018

1 reference

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

21 January 2018

1 reference

Insulin detemir: from concept to clinical experience

21 January 2018

1 reference

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

21 January 2018

1 reference

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes

21 January 2018

1 reference

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension

21 January 2018

1 reference

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

21 January 2018

1 reference

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

21 January 2018

1 reference

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

21 January 2018

1 reference

A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec

21 January 2018

1 reference

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes

21 January 2018

1 reference

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12219

1 reference

29 August 2017

1 reference